PEDIATRICS Vol. 91 No. 6 June 1993, pp. 1218
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by LACKNER, H.
Right arrow Articles by URBAN, CH.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by LACKNER, H.
Right arrow Articles by URBAN, CH.

Which Is the Most Appropriate Dosage of Liposomal Amphotericin-B (AmBisome) for the Treatment of Fungal Infections in Infants of Very Low Birth Weight?

H. LACKNER MD1 and CH. URBAN MD1

1 Dept of Pediatrics, University of Graz, Auenbruggerplatz 13, A-8036 Graz, Austria

In Reply.—

We read with great interest the results of Pereira da Silva and co-workers, who successfully treated two premature newborns with disseminated fungal infection using lower doses of liposomal Amphotericin-B (AmBisome) than we have reported in our paper.1 We agree with the authors that the most appropriate dosage of liposomal Amphotericin-B for the treatment of very low birth weight infants is still to be established, and that the main goal of treatment should be to use AmBisome in a dose with maximal effect but minimal toxicity.